Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Finans |
| Industri | Investeringar |
Venture Targeter AB ("Venture Targeter"), a strategic investment company founded by Katalysen Ventures AB (publ) ("Katalysen Ventures"), has successfully completed its inaugural special situation investment alongside prominent European venture investors. In collaboration with business angels and entrepreneurs, Venture Targeter is pleased to announce its participation in the acquisition of QuTEM (formerly Vironova BioAnalytics) (the "Company"), positioning itself as the second-largest shareholder in the company. Katalysen Ventures, holding a 33% stake in Venture Targeter, further strengthens its commitment to supporting early-stage innovation with the inclusion of Venture Targeter in its portfolio following this milestone transaction.
Venture Targeter is pleased to announce its participation in the acquisition of QuTEM (formerly Vironova BioAnalytics), a leading provider of transmission electron microscopy (TEM) services, alongside QuatreLab (a quality control company created by Columbus Venture Partners) and Accord Investment Partners. This will enable QuTEM to enhance its capabilities and continue to deliver TEM analyses according to Good Manufacturing Practices (GMP) for the pharmaceutical industry. QuTEM has established a strong reputation as a trusted partner for pharmaceutical companies globally, known for its commitment to high-quality standards.
The partnership with Columbus Venture Partners through Quatre Lab, Accord Investment Partners and Venture Targeter brings together valuable experience and new resources for QuTEM. This collaboration will empower QuTEM to expand its services, invest in advanced technologies, and accelerate development efforts. The company will maintain its focus on providing GMP-compliant TEM analyses crucial for pharmaceutical research, development, and quality control.
Josefina Nilsson, CEO of QuTEM (formerly Vironova BioAnalytics), expressed enthusiasm for the acquisition, saying, "We are excited to join forces with these new partners to allow us to provide the pharmaceutical industry with top-quality TEM services, and to expand our capabilities, drive innovation and better serve our clients."
Javier García, co-founder and general partner of Columbus Venture Partners, also expressed his excitement about this acquisition. "Vironova BioAnalytics has a strong track record of delivering precise and reliable TEM analyses. We see potential in this collaboration and are committed to supporting the company's growth and mission in the pharmaceutical sector."